MDS

MDS Inc. Completes Divestiture of MDS Pharma Services Phase II-IV Operations

MDS Pharma Services to Focus on the Delivery of Early Stage Services - Discovery Through Phase IIa TORONTO, July 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ ), a leading provider of products and services to the global life sciences markets, today announced that it has...

MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa

Company to Divest Late Stage Operations, Signs Agreement to Sell Phase II-IV Operations to INC Research TORONTO, June 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ ), a leading provider of products and services to the global life sciences markets, today announced that i...

FertilityTies.com Convention Open to the Public, June 6, 1-5 PM at The Hilton New York Hotel, MDs to Lead Discussion on Timely Fertility Topics

FertilityTies' June 6 convention to offer the online social network the chance to meet one another and the accredited medical professionals who weigh in at the site, topics of interest to be discussed & members' questions answered NEW YORK, May 19 /PRNewswire/ -- FertilityTies ( www.Fer...

Compendia Bioscience Announces Collaboration with MDS Pharma Services to Deliver Novel Solution for Oncology Drug Development

ANN ARBOR, Mich., April 28 /PRNewswire/ -- Compendia Bioscience today announced a strategic collaboration with MDS Pharma Services to deliver OncoPredictor(SM) -- a novel solution for improved cancer drug development. OncoPredictor(SM) combines MDS Pharma Services OncoPanel(TM) with Compendia Bio...

Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS

VIDAZA Restores Gene Function to Double Survival and Increase Transfusion Independence CROSSWICKS, N.J., Feb. 18 /PRNewswire/ -- The Myelodysplastic Syndromes (MDS) Foundation says data published in the peer reviewed medical journal The Lancet Oncology confirms VIDAZA extends survival f...

Long-Term Care Industry Braces for Implementation of MDS 3.0: HCPro Responds with MDSonlineCentral.com

The results of a recent survey on major overhaul of ltc processes for 2009. Marblehead, MA (PRWEB) January 7, 2009 -- Results are in from a national survey of long-term care administrators and MDS coordinators fielded by HCPro, Inc. , a Halyard portfolio company. While...

Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform

EAST FALMOUTH, Mass. and SUNNYVALE, Calif., July 8 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC) and MDS Analytical Technologies are pleased to announce the launch of ACC's Chromogenic LAL Endotoxin assay kits utilizing MDS Analytical Technologies' SpectraMax(R) instrument platform and So...

Dr. Peter Covitz Joins MDS Nordion as Senior Vice-President Innovation

New position created to support growth at MDS Nordion OTTAWA, Feb. 5 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has appointed Dr. Peter Covitz to the newly created position of Senior Vice-President Innovation. Dr. Covitz will...

MDS Issues MDS US GAAP Primer

Preparing Investors for MDS' conversion from Canadian to US GAAP Filing TORONTO, Jan. 25 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today issued an MDS US GAAP Primer in anticipation of filing its 20...

Scoring system identifies MDS patients who have low-risk disease but a poor prognosis

HOUSTON - A new scoring system for a form of leukemia known as myelodysplastic syndrome (MDS) identifies patients who appear to have low-risk disease but actually have poor prospects of survival, researchers at The University of Texas M. D. Anderson Cancer Center report online at the journal Leuke...

MDS in Medical Technology

Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy

NEW HAVEN, Conn., Aug. 19 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Pink Sheets: VION) announced today that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON") to conduct a clinical trial of laromustine (Cloretazine(...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...sitive results from a separate Phase 1-2a study in mds patients involving an intravenous formulation of T...pment of TELINTRA. Phase 2 studies are ongoing in mds (enrollment completion expected by year end), and ...ns are available from Telik. Background on mds and TELINTRA ...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

...at patients with myelodysplastic syndromes (MDS). mds is a potentially life-threatening group of bone ma...ed administration time. If approved, patients with mds may experience increased convenience with the new ...sly treated and untreated, de novo and secondary mds of all French-American-British (FAB) subtypes (ref...

Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

...with a pre-existing haematological malignancy or myelodysplastic syndromes (MDS). Nplate is not indicated for the treatment of thrombocytopenia due to mds or any cause of thrombocytopenia other than chronic ITP. In the U.S. Nplate is available only through a restricted distribution program called...

Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)

...6, and is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary mds of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, re...

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

...ets per microliter. Interim Phase 2 Nplate mds Data Also Presented (Abstract # 224) Inter...g Nplate in patients with low or intermediate risk mds receiving azacytidine were also presented (n=40). ...y hemorrhage. One case of disease progression from mds to acute myeloid leukemia was observed in the Npla...

Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations

...onal pivotal study starting recruitment early 2009. In this study the efficacy of ATIR(TM) will be investigated in patients diagnosed with AML, ALL or mds eligible for an allogeneic bone marrow transplantation but for whom no matching donor is available. "Bone marrow transplantations are often th...

Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union

...s with a pre-existing hematological malignancy or Myelodysplastic Syndrome (MDS). Nplate is not indicated for the treatment of thrombocytopenia due to mds or any cause of thrombocytopenia other than chronic ITP. In the U.S. Nplate is available only through a restricted distribution program called...

Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect

... functions of the company. "I congratulate Dr. Winstanly on his appointment as Chair-Elect of ACRO," said David Spaight, ACRO Chair and President of mds Pharma Services. "His experience and insight will enhance the association's efforts to demonstrate the important contributions that CROs make to the c...

Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

...study, the number of treatment cycles was limited. mds is a potentially life-threatening group of bone ma...nts included in the trial had primary or secondary mds with or without previous therapy with growth facto...were greater than or equal to 18 years of age with mds (de novo or secondary) of any FAB subtype and with...

MDS in Medical Products

Wound Care Manager

Features:...ultation Information: Full SOAP note, Hyper baric Oxygen Treatment, Whirlpool Treatment, Treatment and Care Plan, Recommendations & Outcomes, Generate mds Section M Report, Patient Visit / Follow up Tracker, Wound Glossary Wound Data Features / Fields Include: Location, Type, Significance Factor, Acq...
Company:DDH Software, Inc.

MDS in Medical Definition

Allopathic medicine

...terms were considered highly offensive by those at whom they were directed. The generally uncomplaining acceptance of "allopathic medicine" by today's mds is an indication of both a lack of awareness of the term's historical use and the recent thawing of relations between irregulars and allopaths. – J...

Hematopathology

...llary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , CML ) • MPD Ph- ( Essential thrombocytosis , Polycythemia vera , Myelofibrosis ) • mds • Neutropenia Red blood cells / anemia / hemoglobinopathy Nutritional anemia: ( Iron deficiency anemia , Plummer-Vinson syndrome , Pe...

Pathology

...llary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , CML ) • MPD Ph- ( Essential thrombocytosis , Polycythemia vera , Myelofibrosis ) • mds • Neutropenia Red blood cells / anemia / hemoglobinopathy Nutritional anemia: ( Iron deficiency anemia , Plummer-Vinson syndrome , Pe...

MDS in Medical Dictionary

Aplastic

...edge, concerns, and success stories. Aplastic anemia myelodysplasia mds patient ... Aplastic Anemia Home. Navigation Page. New ... In acquired a...benzene exposure, see our At ... According to the Aplastic Anemia and mds International Foundation 30,000 new ... Ashley is suffering from aplastic ...

MDS in Biological News

The MDS foundation supports vidaza's recommendation for European approval

The Myelodysplastic Syndromes (MDS) Foundation supports the positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of VIDAZA (azacitidine) for specific types of MDS patients, including those with high-risk MDS, chronic myelomonocytic ...

The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data

Crosswicks, NJ (August 22, 2008) The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial. Results from the trial found that azacitidine is the o...

Vidaza receives positve opinion from European CHMP

... The Aplastic Anemia & mds International Foundation is pleased to inform pati...ll, unprecedented survival benefit for higher-risk mds patients. The positive opinion will be forwarded t...Huber, Executive Director of the Aplastic Anemia & mds International Foundation, "Vidaza not only extends...

FDA approves Vidaza label expansion

...ton D.C. (August 21, 2008) The Aplastic Anemia & mds International Foundation (AA&MDSIF) is pleased to ... Vidaza is the only agent that extends survival in mds (myelodysplastic syndromes) patients. Vidaza was a...MDS. Roughly 30 percent of patients diagnosed with mds will progress to AML. "We are very encourage...

Leukemia Drug Breakthrough Study In New England Journal Of Medicine

...ngland Journal of Medicine. Nearly 90 percent of mds patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the mds patients with a chromosome abnormality named 5q mi...hase I clinical trial of Revlimid for treatment of mds following his laboratory observations that the age...

MDS in Biological Technology

Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs

Universities like Stanford, Berkeley, UPenn Partner with Biocareercenter.com to Aid Post-Graduate Students, Alumni SANTA CRUZ, Calif., Oct. 2 /PRNewswire/ -- According to the National Postdoc Association, more than 800,000 life scientists with PhDs and post-doctorates are in the ...

Caprion Proteomics Inc. and Applied Bioystems Work Together to Accelerate Protein Biomarker Verification and Validation

...Copyright 2009. QTRAP is a registered trademark of Applied Biosystems/MDS Analytical Technologies, a joint venture between Applied Biosystems LLC and mds Inc. Caprion Proteomics Inc. Media Didier Jean-Francois Director of Marketing and Business Development Caprion Proteomics In...

Under the Microscope: 'Micro IVF'

... mds Debate Effectiveness of 'Micro IVF,' also referred to as 'Mini IVF' or 'Minimal Stimulation IVF' at FertilityTies.com LOS ANGELES, April 28 /PRNe...

Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies

...or RapidFire(R) technologies." Collaborations with sector leaders such as Applied Biosystems, Agilent Technologies, BD Biosciences, Gene Express, mds Analytical Technologies and Synchron Lab Automation have yielded optimized genotyping systems, end-to-end high-throughput mass spectrometry solutions,...

Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels

...rom top scientists, investors, planters and government officials involved in Jatropha development and distribution. Ten hours of networking with CEOs, mds and top decision-makers in the global Jatropha and biofuel sector is also available to enable beneficial and lucrative business contacts. Jatropha...

Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels

...rom top scientists, investors, planters and government officials involved in Jatropha development and distribution. Ten hours of networking with CEOs, mds and top decision-makers in the global Jatropha and biofuel sector is also available to enable beneficial and lucrative business contacts. Jatropha...

Xceleron Names Michael Butler as President & CEO

...o over $200 million, as well as expand operations from three locations to eight sites globally. Before Aptuit, Dr. Butler was Group Vice President at mds Pharma Services responsible for managing the company's clinical and chemistry operational units. "This is an exciting time to join Xceleron....

BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...share a boost compared to the same quarter last year, although most of the patients on Renvela have been switched from Renagel. Close to two-thirds of mds and over three quarters of RDs have used Renvela in their hemodialysis patients, however, Renagel and FMC's PhosLo remain the two most frequently pres...

Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members

...e association's Board. "I am extremely pleased to welcome Clinilabs and RPS as new members of ACRO," said David Spaight, ACRO Chair and President of mds Pharma Services. "Their involvement will enhance the association's ability to represent the CRO industry broadly to government officials, research spo...

SuperGen Reports 2008 Second Quarter Financial Results

...rch and Treatment of Cancer (EORTC), administered Dacogen on a three-day dosing schedule in which the number of treatment cycles was limited. mds is a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells. Subsequent to database l...

MDS in Biological Products

Shimadzu Phoretix Pro upgrade from Shimadzu Biotech

Description:...ware). Supports advanced statistical tool sets for gel and spots comparison and queries (including finding significant spots, data mining using PCA, mds or CA). Answers questions such as Which spots are similar and/or different in a single experiment? Which gels are similar between different expe...
Company:Shimadzu Biotech

4000 Q TRAP LC/MS/MS System from Applied Biosystems

Description:... Applied Biosystems and mds Sciex present the 4000 Q TRAP(TM) LC/MS/MS System, a high performance hybrid triple quadrupole/linear ion trap mass spectrometer for the drug discover...
Company:Applied Biosystems

MDS in Biological Dictionary

Contiguous gene syndrome

...e to deletion of multiple genes that are ... Miller-Dieker Syndrome : Analysis of a Human Contiguous Gene Syndrome in the Mouse ... with mds being a contiguous - gene syndrome , in which deletion of physically ... A contiguous gene syndrome associated with a heterozygous mic...